EUCTR2011-001953-10-DE进行中（未招募）1 期
A phase 2/3 study of the efficacy and safety of hematopoietic stem cells transduced with Lenti D lentiviral vector for the treatment of cerebral adrenoleukodystrophy (CALD)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Informed consent is obtained from a competent custodial parent or guardian with legal capacity to execute a local IRB/Independent Ethics Committee (IEC) approved consent (informed assent will be sought from capable subjects, in accordance with the directive of the IRB/IEC and with local requirements).
- •2. Males aged 17 years and younger, at the time of parental/guardian consent and, where appropriate, subject assent.
- •3. Active cerebral ALD as defined by:
- •-Elevated VLCFA values, and
- •-Active CNS disease established by central radiographic review
- •of brain MRI demonstrating:
- •i. Loes score between 0.5 and 9 (inclusive) on the 34-point scale, and
- •ii. Gadolinium enhancement on MRI of demyelinating lesions.
- •4. Neurological Function Score (NFS) = 1.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 32
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Receipt of an allogeneic transplant or gene therapy.
- •2. Availability of a willing 10/10 HLA-matched sibling donor (excluding female heterozygotes).
- •3. Use of statins, Lorenzo's Oil, or dietary regimens used to lower VLCFA of consent.
- •4. Receipt of an investigational study drug or procedure within 3 months before Screening that might confound study outcomes. Use of investigational study drugs is prohibited throughout the course of the study.
- •5. Any conditions that make it impossible to perform MRI studies (including allergies to anesthetics or contrast agents).
- •6. Hematological compromise as evidenced by:
- •- Peripheral blood ANC count < 1500 cells/mm3,
- •- Platelet count < 100,000 cells/mm3, or
- •- Hemoglobin < 10 g/dL.
- •- Uncorrected bleeding disorder.
- •7. Hepatic compromise as evidenced by:
- •- Aspartate transaminase (AST) value > 2.5×ULN
- •- Alanine transaminase (ALT) value > 2.5×ULN
- •- Total bilirubin value > 3.0 mg/dL, except if there is a diagnosis of Gilbert's Syndrome and the subject is otherwise stable
- •8. Renal compromise as evidenced by abnormal renal function (actual or calculated creatinine clearance < 50 mL/min)
- •9. Cardiac compromise as evidenced by left ventricular ejection fraction <40%
- •10. Immediate family member with a known or suspected familial cancer syndrome (including but not limited to hereditary breast and ovarian cancer syndrome, hereditary non-polyposis colorectal cancer syndrome, and familial adenomatous polyposis).
- •11. Clinically significant active bacterial, viral, fungal, parasitic, or prionassociated infection
- •12. Positive for human immunodeficiency virus type 1 or 2 (HIV-1, HIV-2); hepatitis B; hepatitis C; human T lymphotrophic virus 1 (HTLV-1). (Note that subjects who have been vaccinated against hepatitis B [hepatitis B surface antibody-positive] who are negative for other markers of prior hepatitis B infection [eg, negative for hepatitis B core antibody (Ab)] are eligible. Subjects with past exposure to HBV [HBcAb positive and/or HBeAb positive] are also eligible for the study provided they have a negative test for HBV DNA. Also note that subjects who are positive for anti-hepatitis C antibody are eligible as long as they have a negative hepatitis C viral load).
- •13. Any clinically significant cardiovascular or pulmonary disease, or other disease or condition that would be contraindicated for any of the other study procedures.
- •14. Absence of adequate contraception for fertile subjects. Male subjects and their female partners are required to use two different effective methods of contraception from Screening through at least 6 months after drug product infusion.
- •15. Any contraindications to the use of G-CSF during the mobilization of hematopoietic stem cells and any contraindications to the use of busulfan and cyclophosphamide, including known hypersensitivity to the active substances or to any of the excipients.
研究者
相似试验
进行中（未招募）
1 期
Clinical study to assess the efficacy and safety of gene therapy for the treatment of childhood cerebral adrenoleukodystrophyChildhood Cerebral Adrenoleukodystrophy (CCALD)MedDRA version: 18.0Level: PTClassification code 10051260Term: AdrenoleukodystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-001953-10-FRbluebird bio, Inc.15
尚未招募
2 期
A clinical study of a herbal formulation DRDC/2022/040 on symptoms of Gastroesophageal reflux disease (GERD)CTRI/2023/08/056221Dabur Research Development Centre Dabur India Limited
已完成
不适用
A Pilot Study to Evaluate Safety and Efficacy of HLA-mismatched Granulocyte Transfusions in the Treatment of Patients with Solid Malignant Tumors Who Are Resistant to Standard Cancer Therapy or for Whom No Standard Cancer Therapy ExistsCTRI/2012/11/003116Munogenics Inc USA22
已完成
不适用
Phase III study on the efficacy and safety of Hypericum extract WS® 5570 in patients with a Major Depressive EpisodeMajor depressive disorderMental and Behavioural DisordersDepressionISRCTN77277298Schwabe Pharmaceuticals (Germany)320
已完成
不适用
Clinical exploratory study on the usefulness of hemodynamic preloading parameters using noninvasive cardiac output measuring device (ClearSight) for perioperative fluid managementJPRN-UMIN000025497Hokkaido Universtiy Graduate School of Medicine, Department of Gastroenterological SurgeryII18